1887

Abstract

Prior to the identification of hepatitis C virus (HCV), transfusion-transmission was common. Viral transmission in subjects with a known date of infection allows the study of the immune responses to acute HCV infection. We analysed 39 soluble immune factors in serum samples from subjects with transfusion-transmitted HCV. Dynamic expression kinetics of interferon gamma-induced protein 10 (IP-10), tumour necrosis factor-alpha and interleukin (IL)-10 were observed during acute HCV infection. Serum IP-10 was the only analyte that was significantly elevated in HCV resolvers compared with uninfected controls. In individuals who progressed to chronic HCV elevated levels of IP-10 and IL-10 coincided with first significant alanine aminotransferase elevation and remained elevated during the first year of acute HCV infection. In addition to monitoring lack of reduction in viral load, serum levels of IP-10 and IL-10 expression during acute HCV infection may be useful biomarkers to predict the progress to chronic HCV.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.041277-0
2012-08-01
2020-07-10
Loading full text...

Full text loading...

/deliver/fulltext/jgv/93/8/1673.html?itemId=/content/journal/jgv/10.1099/vir.0.041277-0&mimeType=html&fmt=ahah

References

  1. Accapezzato D., Francavilla V., Paroli M., Casciaro M., Chircu L. V., Cividini A., Abrignani S., Mondelli M. U., Barnaba V.. 2004; Hepatic expansion of a virus-specific regulatory CD8+ T cell population in chronic hepatitis C virus infection. J Clin Invest113:963–972[PubMed][CrossRef]
    [Google Scholar]
  2. Alter M. J.. 2007; Epidemiology of hepatitis C virus infection. World J Gastroenterol13:2436–2441[PubMed][CrossRef]
    [Google Scholar]
  3. Alter H. J., Conry-Cantilena C., Melpolder J., Tan D., Van Raden M., Herion D., Lau D., Hoofnagle J. H.. 1997; Hepatitis C in asymptomatic blood donors. Hepatology26:Suppl. 129S–33S [CrossRef][PubMed]
    [Google Scholar]
  4. Armstrong G. L., Wasley A., Simard E. P., McQuillan G. M., Kuhnert W. L., Alter M. J.. 2006; The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med144:705–714[PubMed][CrossRef]
    [Google Scholar]
  5. Berres M. L., Trautwein C., Schmeding M., Eurich D., Tacke F., Bahra M., Neuhaus P., Neumann U. P., Wasmuth H. E.. 2011; Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis progression after liver transplantation for hepatitis C infection. Hepatology53:596–603 [CrossRef][PubMed]
    [Google Scholar]
  6. Brooks D. G., Trifilo M. J., Edelmann K. H., Teyton L., McGavern D. B., Oldstone M. B.. 2006; Interleukin-10 determines viral clearance or persistence in vivo. Nat Med12:1301–1309 [CrossRef][PubMed]
    [Google Scholar]
  7. Busch M. P.. 2001; Insights into the epidemiology, natural history and pathogenesis of hepatitis C virus infection from studies of infected donors and blood product recipients. Transfus Clin Biol8:200–206 [CrossRef][PubMed]
    [Google Scholar]
  8. Butera D., Marukian S., Iwamaye A. E., Hembrador E., Chambers T. J., Di Bisceglie A. M., Charles E. D., Talal A. H., Jacobson I. M.. other authors 2005; Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood106:1175–1182 [CrossRef][PubMed]
    [Google Scholar]
  9. Cacciarelli T. V., Martinez O. M., Gish R. G., Villanueva J. C., Krams S. M.. 1996; Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa. Hepatology24:6–9 [CrossRef][PubMed]
    [Google Scholar]
  10. Casrouge A., Decalf J., Ahloulay M., Lababidi C., Mansour H., Vallet-Pichard A., Mallet V., Mottez E., Mapes J.. other authors 2011; Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Invest121:308–317 [CrossRef][PubMed]
    [Google Scholar]
  11. de Jong M. D., Simmons C. P., Thanh T. T., Hien V. M., Smith G. J., Chau T. N., Hoang D. M., Chau N. V., Khanh T. H.. other authors 2006; Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med12:1203–1207 [CrossRef][PubMed]
    [Google Scholar]
  12. Dunn C., Peppa D., Khanna P., Nebbia G., Jones M., Brendish N., Lascar R. M., Brown D., Gilson R. J.. other authors 2009; Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology137:1289–1300 [CrossRef][PubMed]
    [Google Scholar]
  13. Ejrnaes M., Filippi C. M., Martinic M. M., Ling E. M., Togher L. M., Crotty S., von Herrath M. G.. 2006; Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med203:2461–2472 [CrossRef][PubMed]
    [Google Scholar]
  14. Flynn J. K., Dore G. J., Hellard M., Yeung B., Rawlinson W. D., White P. A., Kaldor J. M., Lloyd A. R., Ffrench R. A.. ATAHC Study Group 2011; Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users. J Viral Hepat18:549–561 [CrossRef][PubMed]
    [Google Scholar]
  15. Lavanchy D.. 2009; The global burden of hepatitis C. Liver Int29:Suppl. 174–81 [CrossRef][PubMed]
    [Google Scholar]
  16. Marcellin P.. 1999; Hepatitis C: the clinical spectrum of the disease. J Hepatol31:Suppl. 19–16 [CrossRef][PubMed]
    [Google Scholar]
  17. Mosley J. W., Operskalski E. A., Tobler L. H., Buskell Z. J., Andrews W. W., Phelps B., Dockter J., Giachetti C., Seeff L. B.. other authors 2008; The course of hepatitis C viraemia in transfusion recipients prior to availability of antiviral therapy. J Viral Hepat15:120–128 [CrossRef][PubMed]
    [Google Scholar]
  18. Seeff L. B., Hollinger F. B., Alter H. J., Wright E. C., Cain C. M., Buskell Z. J., Ishak K. G., Iber F. L., Toro D.. other authors 2001; Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a national heart, lung, and blood institute collaborative study. Hepatology33:455–463 [CrossRef][PubMed]
    [Google Scholar]
  19. Selvarajah S., Tobler L. H., Simmons G., Busch M. P.. 2010; Host genetic basis for hepatitis C virus clearance: a role for blood collection centers. Curr Opin Hematol17:550–557 [CrossRef][PubMed]
    [Google Scholar]
  20. Stacey A. R., Norris P. J., Qin L., Haygreen E. A., Taylor E., Heitman J., Lebedeva M., DeCamp A., Li D.. other authors 2009; Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol83:3719–3733 [CrossRef][PubMed]
    [Google Scholar]
  21. Thomson E. C., Fleming V. M., Main J., Klenerman P., Weber J., Eliahoo J., Smith J., McClure M. O., Karayiannis P.. 2011; Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut60:837–845 [CrossRef][PubMed]
    [Google Scholar]
  22. Tobler L. H., Cameron M. J., Lanteri M. C., Prince H. E., Danesh A., Persad D., Lanciotti R. S., Norris P. J., Kelvin D. J., Busch M. P.. 2008; Interferon and interferon-induced chemokine expression is associated with control of acute viremia in West Nile virus-infected blood donors. J Infect Dis198:979–983 [CrossRef][PubMed]
    [Google Scholar]
  23. Yoneda S., Umemura T., Joshita S., Ichijo T., Matsumoto A., Yoshizawa K., Katsuyama Y., Ota M., Tanaka E.. and the Nagano Interferon Treatment Research Group 2011a; Serum chemokine levels are associated with the outcome of pegylated interferon and ribavirin therapy in patients with chronic hepatitis C. Hepatol Res41:587–593 [CrossRef][PubMed]
    [Google Scholar]
  24. Yoneda S., Umemura T., Katsuyama Y., Kamijo A., Joshita S., Komatsu M., Ichijo T., Matsumoto A., Yoshizawa K.. other authors 2011b; Association of serum cytokine levels with treatment response to pegylated interferon and ribavirin therapy in genotype 1 chronic hepatitis C patients. J Infect Dis203:1087–1095 [CrossRef][PubMed]
    [Google Scholar]
  25. Zeremski M., Dimova R., Brown Q., Jacobson I. M., Markatou M., Talal A. H.. 2009; Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection. J Infect Dis200:1774–1780 [CrossRef][PubMed]
    [Google Scholar]
  26. Zeremski M., Hooker G., Shu M. A., Winkelstein E., Brown Q., Des Jarlais D. C., Tobler L. H., Rehermann B., Busch M. P.. other authors 2011; Induction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infection. J Hepatol55:545–553 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.041277-0
Loading
/content/journal/jgv/10.1099/vir.0.041277-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error